LGALS3 and ovarian carcinoma: In contrast to our previous observations in the ovarian cancer cell line, we did not see an increase in drug sensitivity in the Gal3-KO cells following treatment with carboplatin when compared to Gal3-CTRL cells and instead detected drug resistance (Fig. 2h, i).